MTA-1和Ezrin在乳腺癌组织中的表达及其相关性探讨

Expression of MTA-1 and Ezrin and theirs correlation with clinical and pathology in breast cancer

目的探讨肿瘤转移相关基因MTA-1和细胞骨架连结蛋白Ezrin在乳腺癌组织中的表达及两者之间的相关性和与乳腺癌临床病理的关系。方法分别应用分子原位杂交及免疫组织化学SP法检测80例乳腺癌组织和15例正常乳腺组织中MTA-1 mRNA、Ezrin蛋白的表达,分析两者之间的相关性及与乳腺癌患者病理类型、年龄、临床分期、淋巴结转移等参数的关系。结果正常乳腺组织MTA-1 mRNA(13.3%)、Ezrin蛋白(20.0%)的表达率明显低于乳腺癌组织中MTA-1 mRNA(66.2%)和Ezrin蛋白(68.7%)的表达率,P<0.05;MTA-1 mRNA与Ezrin蛋白的表达呈正相关(r=0.634,P=0.000);MTA-1 mRNA和Ezrin蛋白在乳腺癌中的表达与肿瘤临床分期和淋巴结转移状态相关,P值均<0.05;与患者年龄、肿瘤大小、病理类型无相关性,P值均>0.05。MTA-1+/Ezrin+组的无病生存率低于MTA-1-/Ezrin-组(χ2=7.610,P=0.006)。结论提示MTA-1和Ezrin在肿瘤转移中具有协同作用,高表达组患者的临床预后差与肿瘤淋巴转移有关。

[Objectives] To investigate the expression of matastasis associated gene 1 （MTA-1） and membraneeytoskeleton protein （Ezrin） in breast cancers and theirs correlation with the clinical and pathology. [Methods] The expressions of MTA-lmRNA and Ezrin in 80 eases of breast cancer and 15 eases of normal breast tissues were detected by immunihistoehemistry SP in situ hybridization and method respectively. Analyzed theirs correlation with the parameters such as clinical stage, pathologic type, lymphnode matastasis et al, and studied theirs correlation with each other and effect on prognosis of breast cancer. [Results] The positive rates of MTA-lmRNA and Ezrin in breast cancers were 66.2% （53/80） and 68.7% （55/80） respectively. The darns were significantly higher than that in normal breast tissues, which were 13：3% （2/15） and 20.0% （3/15） respectively, （P 〈0.05）. The positive rate of MTA-1 mRNA and Ezrin in clinical stage Ⅲ and Ⅳ of breast cancers were 83.8% （26/31） and 87.0% （27/31）, while that in ~linieal stage Ⅰ and Ⅱ of breast cancers were 46.9% （23/49） and 48.9% （24/49） respectively. There have significantly difference in both MTA- 1mRNA and Ezrin between the different stages （P 〈0.05）. The positive rate of MTA-1mRNA in those eases of lymphnode matastasis group was 86.9% （40/46）, while that was 41.1% （14/34） in the non-lymphnode matastasis group. There has significant difference between the corresponding two groups. While the difference of the positive rates in different groups of age, tumor in size and pathological type were insignificant （P 〉 0.05）. The positive rate of Ezrin in the cases of lymphnode matastasis group （89.1%） was higher than that （47.0%） in the non-lymphnode matastasis group. There has significant difference between the corresponding two groups （P 〈 0.05）. While the differe/ice of the positive rates in different groups of age, tumor in size and pathological type were insignificant （P 〉0.05）. The expression of MTA-1 in breast cancer was positively related to Ezrin. （r =0.634, P = 0.000）. The ratio of Disease-Free survival in group of MTA-12＋/Ezrin2＋ was significantly lower than that in group MTA-1□/Ezrin□1 （χ2=7.610, P=0.006） in breast cancer. [Conclusions] These results indicated that there were correlations between the high expression of MTA-1 and Ezrin with occurrence of breast cancer, detected MTA-1 and Ezrin expression in breast cancer could supply the evidence for clinical therapy and judgement of prognosis.